ObsEva - OBSV Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ObsEva in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OBSV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OBSV, but not buy additional shares or sell existing shares.
View OBSV analyst ratings or view top-rated stocks.

5 equities research analysts have issued 1 year price targets for ObsEva's shares. Their OBSV share price forecasts range from $1.00 to $12.00. On average, they anticipate the company's stock price to reach $8.40 in the next year. This suggests a possible upside of 6,988.6% from the stock's current price.
View analysts price targets for OBSV or view top-rated stocks among Wall Street analysts.

ObsEva's stock was trading at $0.1450 on January 1st, 2023. Since then, OBSV shares have decreased by 18.3% and is now trading at $0.1185.
View the best growth stocks for 2023 here.

ObsEva saw a increase in short interest in February. As of February 28th, there was short interest totaling 719,300 shares, an increase of 50.9% from the February 13th total of 476,600 shares. Based on an average daily trading volume, of 7,080,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.7% of the shares of the company are sold short.
View ObsEva's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our OBSV earnings forecast.

ObsEva SA (NASDAQ:OBSV) posted its earnings results on Thursday, November, 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.23.

Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).

(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

ObsEva trades on the NASDAQ under the ticker symbol "OBSV."

ObsEva's stock is owned by many different retail and institutional investors. Top institutional investors include Credit Suisse AG (2.25%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OBSV stock can currently be purchased for approximately $0.12.

ObsEva (NASDAQ:OBSV) has a market capitalization of $9.24 million and generates $20.11 million in revenue each year. The company earns $-58,380,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The official website for the company is www.obseva.com. The company can be reached via phone at (122) 552-3840 or via email at ir@obseva.ch.